Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Specifically, retatrutide simultaneously activates three incretin and metabolic hormone receptors: GLP-1 (glucagon-like peptide-1) receptor which reduces appetite and slows gastric emptying [6] [7] GIP (glucose-dependent insulinotropic polypeptide) receptor which enhances insulin secretion and may improve fat metabolism [9] [10] Glucagon receptor which may increase energy expenditure and, based on early clinical and preclinical data, could promote hepatic fat metabolism This triple-action mechanism sets retatrutide apart from existing approved therapies such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist)
This can lead to symptoms such as feeling sick, throwing up, tiredness, loss of appetite, muscle cramps, itching, and changes in mental function
Alterations in energy metabolism of hypertrophied rat cardiomyocytes: influence of propionyl-L-carnitine
Biological chemistry , 390 (3), 191-214
It is not a steroid
US$ 25.83
US$ 21.02
US$ 27.55
